Stability of refrigerated miglustat after preparation in InOrpha® flavored suspending excipient for compounding of oral solutions and suspensions
Sofyen Riahi, Michael Ambühl, Jürgen Stichler, Dirk Bandilla Actelion Pharmaceuticals Ltd, Allschwil, Switzerland Background: Miglustat (Zavesca®) is an oral treatment for type 1 Gaucher disease and Niemann–Pick disease type C. Patients with Niemann–Pick disease type C often have difficulties swallo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2015-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|